

IN THE CLAIMS

BL
125. (Amended) A composition comprising a compound according to any one of claims 102-104 and a carrier.

REMARKS

Claims 76, 102-107, 118 and 125-128 are pending.

Applicants affirm that the elected species is the first compound listed in claim 103, i.e., compound Q.

Applicants have amended claim 125 in response to the Examiner's rejections (see below).

None of these amendments adds new matter.

THE REJECTIONS

Section 112, First Paragraph

Claim 125 stands rejected under 35 U.S.C. § 112, first paragraph, as lacking enablement. The Examiner has based this rejection on the recitation of the term "pharmaceutical." The Examiner contends that there is no evidence establishing that a pharmaceutical composition comprising a compound that inhibits interleukin-1 β converting enzyme ("ICE") would be therapeutically beneficial. The Examiner has suggested that applicants amend claim 125 to delete the term "pharmaceutical." Applicants traverse.

Applicants disagree that claim 125 lacks enablement due to the recitation of the term "pharmaceutical." To advance prosecution, applicants have nevertheless amended